The results reveal that the OS and PFS of patients in the VRK1 high expression group were significantly lower than those in the VRK1 low expression group (p < 0.05), which was also comparable to the immunohistochemistry results that patients with high VRK1 expression had worse tumor differentiation than patients with low VRK1 expression. This evidence concerns the gene VRK1 and neoplasm.